Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 56 Lung Neoplasms 29 Triple Negative Breast Neoplasms 13 Breast Neoplasms 13 Ovarian Neoplasms 12 Endometrial Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 11 Small Cell Lung Carcinoma 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 11 Neoplasms 10 Fallopian Tube Neoplasms 10 Neoplasm Metastasis 8 Colorectal Neoplasms 5 Adenocarcinoma of Lung 5 Carcinoma 4 Pancreatic Neoplasms 3 Oropharyngeal Neoplasms 3 Melanoma 3 Lung Diseases 3 Esophageal Neoplasms 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Thoracic Neoplasms 2 Sarcoma 2 Respiratory Tract Neoplasms 2 Respiratory Tract Diseases 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Pathologic Complete Response 2 Non-squamous Non-small Cell Lung Cancer 2

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Carboplatin × 30 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡